Fulcrum Therapeutics Inc FULC

NAS: FULC | ISIN: US3596161097 30/04/2025

3,850 USD (+5,48%)

(+5,48%) 30/04/2025

Grafiek Fulcrum Therapeutics Inc

Grafiek Fulcrum Therapeutics Inc

1 dag1d 5,48%
1 week1w 9,69%
1 maand1m 39,49%
3 maanden3m 1,05%
6 maanden6m 19,94%
1 jaar1j -47,48%
5 jaar5j -71,86%

donderdag 1 mei 2025, 13:00

Kwartaalcijfers (1ste kwartaal)

Fulcrum Therapeutics Inc in het nieuws

Toon enkel gratis nieuws

20 juni 2023 · FULC Investors Have Opportunity to Lead Fulcrum Therapeutics, Inc. Securities Fraud Lawsuit · Persbericht

31 mei 2023 · FULC Investors Have Opportunity to Lead Fulcrum Therapeutics, Inc. Securities Fraud Lawsuit · Persbericht

18 maart 2021 · Fulcrum Therapeutics Presents Data for Potential FSHD Biomarker and Clinical Outcome Assessments at 2021 Muscular Dystrophy Association (MDA) Virtual Clinical & Scientific Conference · Persbericht

4 maart 2021 · Fulcrum Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results · Persbericht

26 februari 2021 · Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast on Thursday, March 4, 2021 at 8:00 a.m. ET · Persbericht

26 februari 2021 · Fulcrum Therapeutics Recognizes Rare Disease Day 2021 · Persbericht

22 januari 2021 · Fulcrum Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares · Persbericht

20 januari 2021 · Fulcrum Therapeutics Announces Pricing of Public Offering of Common Stock · Persbericht

19 januari 2021 · Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock · Persbericht

19 januari 2021 · Fulcrum Therapeutics Announces Promotion of Christopher Moxham, Ph.D., to Chief Scientific Officer · Persbericht

Profiel Fulcrum Therapeutics Inc

Gezondheidstechnologie

Medicinale en botanische productie

Werknemers: 111

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe